2137 — Brii Biosciences Income Statement
0.000.00%
Last trade - 00:00- HK$1.44bn
- -HK$1.06bn
Annual income statement for Brii Biosciences, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 51.6 | 0.617 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 1,282 | 4,190 | 541 | 184 | 510 |
| Operating Profit | -1,282 | -4,190 | -489 | -184 | -510 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -1,284 | -4,191 | -490 | -184 | -512 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1,284 | -4,191 | -490 | -184 | -512 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -1,190 | -4,164 | -484 | -175 | -508 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1,190 | -4,164 | -484 | -175 | -508 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.66 | -9.41 | -0.669 | -0.414 | -0.696 |
| Dividends per Share |